Cyclacel Pharmaceuticals, Inc. reported earnings results for the full year ended December 31, 2022. For the full year, the company reported net loss was USD 21.2 million compared to USD 18.89 million a year ago. Basic loss per share from continuing operations was USD 28.5 compared to USD 32.1 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.32 USD | +9.95% | -12.45% | -13.11% |
05-02 | Cyclacel Pharmaceuticals, Inc. announced that it has received $8.000001 million in funding | CI |
04-30 | Top Midday Gainers | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-13.11% | 3.06M | |
+2.93% | 108B | |
-5.27% | 23.46B | |
-14.60% | 21.72B | |
-7.05% | 18.64B | |
-38.55% | 17.45B | |
-8.83% | 17.19B | |
+5.51% | 13.99B | |
+37.49% | 12.53B | |
+329.39% | 8.81B |
- Stock Market
- Equities
- CYCC Stock
- News Cyclacel Pharmaceuticals, Inc.
- Cyclacel Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022